Conference Coverage

Sucroferric Oxyhydroxide Reduces Pill Burden Compared to Sevelamer

San Diego—In a study conducted among Japanese hemodialysis patients with hyperphosphatemia, PA 21 (sucroferric oxyhydroxide [SFOH]) showed a significant serum phosphorus reduction compared with sevelamer hydrochloride (HCI). That was among the findings of a randomized, open-label, parallel-group, multicenter, active-controlled phase 3 study reported during a poster session at Kidney Week 2015. Fumihiko Koiwa, MD, PhD, and colleagues reported the study ... Read More »

Association Between Serum Potassium and Mortality in Dialysis Patients

Dallas—A study conducted by Georges N. Nakhoul, MD, and colleagues at the Cleveland Clinic Foundation, Cleveland, Ohio, identified an association between serum potassium and mortality in patients on dialysis. The researchers reported their findings during a poster session at the NKF Spring Clinical Meetings in a poster titled Serum Potassium, ESRD and Mortality in Chronic Kidney Disease. The role of ... Read More »

Use of Antianemic Agents with Sucroferric Oxyhydroxide

Dallas—Over a 1-year study period, researchers observed similar trends in the use of concomitant intravenous (IV) iron and erythropoiesis-stimulating agents (ESAs) among dialysis patients with hyperphosphatemia who received sucroferric oxyhydroxide and patients who received sevelamer carbonate. That was the primary finding of a randomized, open-label, phase 3 study completed recently by Stuart Sprague, DO, and colleagues and reported during a ... Read More »

Prevalence of Diabetes in CKD Population Increased Over Time

Dallas—The leading cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) in the United States is diabetes mellitus. Kidney function declines with age and the highest prevalence of ESRD is in the elderly US population. Yunnuo Zhu, MPH, and colleagues recently conducted an analysis to examine the trends in diabetes prevalence among the elderly in both the US ... Read More »

Efficacy and Safety of Modified-Release Calcifediol in Stage 3 and 4 CKD

Dallas—Despite treatment with vitamin D therapy, patients with chronic kidney disease (CKD) often have vitamin D insufficiency as well as uncontrolled secondary hyperparathyroidism (SHPT). Modified-release calcifediol corrects vitamin D insufficiency and results in improvement in secondary hyperparathyroidism. Stuart Sprague, DO, and colleagues reported on two trials designed to evaluate whether modified-release calcifediol can effectively treat SHPT in patients with stage ... Read More »